Add to my selection

PEDMARQSI (thiosulfate de sodium)

Medicine - Posted on Jun 05 2025

Active substance (DCI)

thiosulfate de sodium

history (2)

5/28/25

PEDMARQSI (thiosulfate de sodium) - Prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age.

Summary of opinion Unfavourable opinion for reimbursement in the MA indication: “Prevention of ototoxicity induced by cispla...

CAV :
54321

icône flèche
4/10/25

PEDMARQSI (thiosulfate de sodium) - Prévention de l’ototoxicité du cisplatine

Autorisation d’accès précoce refusée à la spécialité PEDMARQSI (thiosulfate de sodium) dans l'indication « prévention de l’o...

icône flèche

Technical information

ATC code

V03AB06

Manufacturer

NORGINE SAS

Presentation

PEDMARQSI 80 mg/mL, solution pour perfusion
1 flacon en verre de 100 ml (CIP : 34009 551 042 3 0)

All our publications

Anemia and hemoglobinopathies

Congenital, genetic and rare diseases

Female genital diseases

Genital cancers

Metabolic diseases

Urologic diseases - miscellaneous